Prostate cancer (PCa) is the most common type of cancer found in American men, other than skin cancer. The American Cancer Society estimates that there will be 186,320 new cases of prostate cancer in the United States in 2008. About 28,660 men will die of this disease this year and PCa remains the second-leading cause of cancer death in men. One in six men will get PCa during his lifetime and one in 35 will die of the disease. Today, more than 2 million men in the United States who have had PCa are still alive. The death rate for PCa continues to decline, chiefly due to early detection and treatment, and improved salvage therapy such as hormone therapy (HT). HT continues to be a mainstay for primary-recurrent PCa and locallyadvanced PCa. However, HT is associated with many undesirable side effects including sexual dysfunction, osteoporosis and hot flashes, all of which can lead to decreased quality of life (QOL). These risks are seen in both long-and short-term HT regimens. Additionally, research in recent years has revealed trends related to clinico pathological variables and their predictive ability in HT outcomes. Awareness of the potential adverse effects, the risks associated with HT and the prognostic ability of clinical and pathological variables is important in determining optimal therapy for individual patients. A rigorous evaluation of the current scientific literature associated with HT was conducted with the goal of identifying the most favorable balance of benefits and risks associated with HT.
Risks and benefits of hormonal therapy
Since Huggins and Hodges discovered that prostate cancer (PCa) cell growth is androgen dependent, hormonal therapy (HT) has been increasingly utilized for the treatment of PCa [Huggins and Hodges, 1972; Huggins, 1967; Huggins and Hodges, 1941] . Approximately 30% of the existing 2 million PCa patients receive HT in the context of adjuvant/neo-adjuvant therapy before or after radical prostatectomy (RP) or external radiotherapy (XRT) [Smith, 2007] . HT has become an increasingly common treatment for organ-confined PCa in the United States over the last decade [Barry et al. 2006; Cooperberg et al. 2003 ]. With this increase in popularity, patients are now receiving HT for extended periods of time. HT is not without risk, however, and is associated with numerous side effects including vasomotor flushing, loss of libido, erectile dysfunction, cognitive decline, arterial stiffness, anemia, fatigue, gynecomastia, mastodynia, osteoporosis leading to fractures, obesity, sarcopenia, and cardiovascular disease [Isbarn et al. 2008; Michaelson et al. 2008; Higano, 2003 ]. More recently, metabolic complications including insulin resistance, diabetes, dyslipidemia and metabolic syndrome have been observed in patients receiving HT. These findings have led some to suggest they are potential explanations for the increased cardiovascular mortality seen in this population [Hakimian et al. 2008; Saigal et al. 2007; Tsai et al. 2007; Keating et al. 2006; Smith et al. 2006b; Yannucci et al. 2006 ], though some studies have found no increase in cardiovascular mortality for men on androgen deprivation therapy (ADT) [Efstathiou et al. 2009 ]. Given the large side-effect profile of HT, it is understandable that HT is associated with decreased quality of life (QOL) [Fowler et al. 2002] .
Prostate-specific antigen (PSA) recurrence Patients with biochemical recurrence or PSA recurrence (PSAR), an increase in PSA to greater than 0.2 ng/ml following curative therapy, continue to be the main subjects utilizing HT as it has not been shown to be superior to current treatments as a primary therapy for PCa [Akaza et al. 2006 ]. Curative treatments such as radical prostatectomy (RP) are effective for clinicallylocalized PCa, however, up to 40% of men will have biochemical evidence of cancer progression, evident as a detectable serum PSA level within 10 years following initial treatment [Amling et al. 2000; Pound et al. 1999; Catalona and Smith, 1994; Zincke et al. 1994] . As a result, it is important to be familiar with the key risk factors for PSAR following curative treatment. Risk factors include age, race, clinical and pathological stage, Gleason score (GS), PSA and small prostate size [Khatami et al. 2007; Freedland et al. 2005; Moul et al. 2001] .
With the growing number of patients on HT and limited data available on optimal treatment regimens, it is important to consider the risks and benefits associated with each therapeutic option. This article focuses on the risks and benefits associated with HT, as well as strategies for stratifying patients in order to achieve maximal benefits while effectively balancing risks.
Methods of HT
Castration remains the gold standard of HT. It is accomplished in one of two ways that have been shown to be equally effective medical and surgical castration [Seidenfeld et al. 2000; Vogelzang et al. 1995; Kaisary et al. 1991] . Medical castration is accomplished through the administration of a luteinizing hormone-releasing hormone (LHRH) agonist, anti-androgen, LHRH pure-antagonist, complete androgen blockade (CAB, castration + anti-androgen) or triple androgen blockade (CAB + 5a-reductase inhibitor). Other pharmacological options are available, but rarely utilized due to unacceptable clinical side effects [The Veterans Administration Co-Operative Urological Research Group, 1967] or decreased efficacy. Surgical castration on the other hand is accomplished through bilateral orchiectomy. Both medical and surgical castration achieve similar therapeutic goals, although they do so in different ways and, consequently, have different associated risks and benefits.
Medical castration

LHRH agonists
Since the introduction of LHRH agonists in the early 1980s, their use in the treatment of PCa has continued to increase. LHRH agonists work primarily through reducing active levels of androgens. Currently available LHRH agonists include leuprorelin, goserelin, triptorelin, and buserelin. More recently, sustained-release formulations that require dosing every 112 months have become available. Today, LHRH agonists are the most common form of HT [Boccon-Gibod, 2005] and the most extensively studied.
Anti-androgens
Nonsteroidal anti-androgens are another popular form of HT, in large part due to the decreased sexual side effects as compared to LHRH agonists or orchiectomy [Dreicer, 2000] . Anti-androgens work by blocking androgen receptors, which keeps circulating androgen levels normal or increased. Currently available agents include flutamide, nilutamide and bicalutamide. With the lack of randomized controlled trials, limited recommendations for anti-androgen monotherapy exist.
Combined androgen blockade and triple androgen blockade
Combined androgen blockage (CAB) is a combination therapy which includes medical or surgical castration combined with an anti-androgen. It is also referred to as maximal androgen blockade (MAB).
CAB has been investigated in many different trials, but with conflicting results. In 1989, Crawford and colleagues with a cohort of 603 men with disseminated, untreated PCa, showed a 25% survival advantage (35.6 vs 28.3 months) in those receiving leuprolide with flutamide (CAB) versus those receiving leuprolide plus placebo [Crawford et al. 1989] . A decade later however, Eisenberger and colleagues found no difference in survival in 1387 men with metastatic PCa who were treated with castration +/À flutamide [Eisenberger et al. 1998 ]. More recently, a meta-analysis of 30 trials showed that, at 5 years, treatment with CAB versus castration was associated with a small, clinically insignificant survival advantage of 23% when compared to castration alone [Prostate Cancer Trialists' Collaborative Group, 2000 ]. These findings were confirmed in 2006 in a systematic review by Lukka et al. [Lukka et al. 2006 ]. Both studies questioned the benefit of CAB given the increased side effects and potential decreased QOL associated with treatment. A recent review found more support for CAB, primarily due to a potential for more effective androgen blockade with bicalutamide [Klotz, 2008] . Currently, monotherapy through orchiectomy or LHRH agonist, rather than CAB is recommended for the treatment of men with recurrent PCa.
Triple androgen blockage (TAB) is CAB with the addition of a 5a-reductase inhibitor. TAB has been studied far less than CAB. Initial results from Leibowitz and Tucker in 2001 showed TAB with finasteride maintenance to be promising [Leibowitz and Tucker, 2001] . However, little data has been published since with no trials supporting its use over the currently available therapies.
Pure LHRH antagonists LHRH antagonists are one of the newer forms of HT and work by blocking LHRH receptors. The major advantage of these drugs is the absence of biochemical flare, a transient increase in testosterone associated with the initiation of androgen deprivation therapy (ADT). Abarelix, the first LHRH antagonist, was as effective as leuprolide at suppressing testosterone, but was taken off the market due to an increased rate of immediateonset systemic allergic reactions [Trachtenberg et al. 2002; Mcleod et al. 2001; Tomera et al. 2001] . More recently, degarelix has been introduced and has not been associated with allergic reactions . To date there have been no long-term trials examining the efficacy of LHRH antagonists versus the currently available therapies.
Surgical castration
Bilateral orchiectomy as a treatment for advanced PCa was first investigated by Huggins and Hodges in a study of 21 patients with metastatic PCa. Of those treated, 15 had either subjective or objective improvement of pain or neurologic symptoms [Huggins and Hodges, 1941] . Orchiectomy is a relatively simple, minimallyinvasive procedure that is easy to perform [Loblaw et al. 2007 ]. It remains the most popular HT method in developing countries [Deng et al. 2004 ]. However, with the advent of viable medical alternatives, and because of the physical and psychological discomforts and irreversibility of orchiectomy, surgical castration has fallen out of favor in developed countries [Mcleod, 2003; Clark et al. 2001 ].
The role of hormone therapy in prostate cancer
Hormone therapy as a primary therapy for localized prostate cancer There is currently no evidence supporting the use of HT in patients with localized PCa. Iversen and colleagues in a randomized controlled trial with 1,218 patients showed that treatment with 150 mg/day of bicalutamide in men with early, nonmetastatic PCa did not significantly improve survival. In fact, a trend toward decreased overall survival was seen in the group receiving bicalutamide [Iversen et al. 2006 ]. The American Urological Association (AUA) guidelines state that primary ADT may be employed with the goal of providing symptomatic control of PCa for patients in whom definitive treatment with surgery or radiation is neither possible nor acceptable. Today, neither the AUA or the European Association of Urology (EAU) recommends the use of HT as primary therapy for PCa in patients with localized disease who are candidates for other treatment [Heidenreich et al. 2008; Thompson et al. 2007] .
Hormone therapy as a primary therapy for locally advanced or metastatic disease For patients with metastatic disease, HT has been shown to provide quality-of-life improvements including reduction in fractures, bone pain and ureteral obstruction [Huggins et al. 1941; Huggins, 1967] . A systematic review and meta-analysis of 24 single-therapy HT trials for men with advanced PCa showed no difference in survival between LHRH agonist and orchiectomy groups, though data showed a trend toward decreased survival in patients treated with antiandrogens [Seidenfeld et al. 2000 ]. This finding was confirmed by Tyrell and colleagues in a prospective trial including 1,453 men with locallyadvanced or metastatic PCa. Treatment with bicalutamide versus castration was found to be less effective for patients with metastatic disease. No survival difference was seen for patients with locally-advanced disease ]. The authors did point out the significant decrease in sexual side effects in patients treated with bicalutamide and that it could be used in patients for whom surgical and medical castration is not indicated or acceptable. Wirth and associates recently reported 7-year results from the Early Prostate Cancer program which randomized men to standard of care (RP, radiation or watchful waiting) +/À bicalutamide. At 7 years, men with locally-advanced disease receiving bicalutamide, showed a 34% reduction in progression-free survival, but no difference in overall survival [Wirth et al. 2007 ]. CAB has also been explored in patients with metastatic disease. In the largest trial to date, Eisenberger and colleagues found no difference in survival in 1,387 men with metastatic PCa who were treated with castration +/À flutamide [Eisenberger et al. 1998 ].
A number of other studies have examined the efficacy of HT in patients with locally-advanced or metastatic disease that looked at immediate versus delayed treatment delivery. These studies are discussed below. The AUA and EAU currently recommend treating patients with asymptomatic metastatic PCa with HT, however, the optimal time to initiate treatment is unknown. For patients with symptomatic metastatic PCa, HT should be initiated immediately.
Hormone therapy combined with radical prostatectomy
Neo-adjuvant therapy with prostatectomy. There is little evidence to suggest that neo-adjuvant LHRH agonists with RP are of any survival benefit. Boorjian and associates showed, in a retrospective trial of 507 men, 455 of which were treated with HT, that adjuvant HT decreased the risk of PSAR and local recurrence, but did not significantly affect overall survival [Boorjian et al. 2007] . Recently a large Cochrane meta-analysis demonstrated that neo-adjuvant HT (LHRH agonists and anti-androgens) can significantly improve adverse pathological characteristics including positive margins, and tumor stage, but does not improve overall survival [Kumar et al. 2006 ]. Currently, neo-adjuvant HT with RP is not recommended by the AUA or EAU.
Adjuvant therapy with prostatectomy. A number of trials have shown that adjuvant HT following prostatectomy does not increase survival as compared to prostatectomy alone. In one of the largest trials to date the Early Prostate Cancer program Wirth and colleagues showed that patients receiving adjuvant bicalutamide had no advantage in survival over those receiving placebo [Wirth et al. 2007] . In another retrospective trial by Siddiqui and colleagues, ADT following RP was associated with increased progressionfree survival and cancer-specific survival. However, it was not found to increase overall survival [Siddiqui et al. 2008] . Finally, for patients with lymph-node metastases, Boorjian and associates found that ADT was associated with a significantly reduced risk of PSAR and local recurrence, but did not demonstrate a survival advantage [Boorjian et al. 2007 ].
The only circumstance in which adjuvant HT with RP has been shown to increase survival was in a small study of 98 men with lymphnode metastases. The study assigned patients to immediate or delayed ADT and after nearly 12 years of follow up, found that those who received immediate HT had significantly increased overall survival [Messing et al. 2006 ]. The study has been criticized though due to its small size and lack of generalizability to the population at large.
Currently, there is no evidence to suggest that neoadjuvant or adjuvant HT with RP provides any overall survival benefit in patients without lymph-node metastases and as such, neither neo-adjuvant nor adjuvant HT with RP is currently recommended by the AUA or EAU. For patients with lymph-node positivity, the EAU recommends immediate ADT whereas the AUA does not address the situation in their guidelines.
Hormone therapy combined with radiation therapy
Neoadjuvant radiotherapy. ADT with radiotherapy has been shown to significantly increase overall survival in a number of studies. Bolla, in a randomized trial with a cohort of 415 men with locally-advanced PCa, showed that the addition of an LHRH agonist (goserelin) to radiotherapy significantly improved overall survival at 5 years (78 versus 62% with radiotherapy alone) [Bolla, 1997] . Pilepich and colleagues also found that the addition of an LHRH agonist to radiotherapy significantly decreased disease-specific death rates at 10 years in men with locally-advanced disease (16 versus 22%) [Pilepich et al. 2005 ]. Of particular interest was the finding that improved survival appeared preferentially in patients with a GS of !7. Additionally, Iversen and colleagues showed that 150 mg/day of bicalutamide in addition to radiation therapy reduced the risk of death by 35% in men with locallyadvanced disease. Additional studies have shown a survival advantage in men receiving neoadjuvant-or adjuvant-combined androgen blockade (LHRH agonist + anti-androgen) with radiotherapy.
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Another study by D'amico and colleagues also demonstrated a survival advantage in men receiving adjuvant HT (LHRH agonist + anti-androgen) with radiotherapy [D'amico et al. 2004] . Additional studies have shown neoadjuvant HT with radiotherapy significantly increases overall survival [Denham et al. 2005; Laverdiere et al. 2004] . Currently, both the AUA and EAU recommend neo-adjuvant and adjuvant HT for patients with high-grade or locally-advanced PCa who will be receiving radiotherapy [Heidenreich et al. 2008; Thompson et al. 2007] .
Hormone therapy combined with other treatment modalities for prostate cancer HT is often given to patients before treatments such as brachytherapy to reduce the size of the prostate [Lee, 2002] . However, a number of studies have shown that neo-adjuvant ADT with brachytherapy does not lead to increased survival [Merrick et al. 2007; Machtens et al. 2006; Galalae et al. 2004] . One retrospective study found that men receiving neo-adjuvant ADT with brachytherapy had significantly reduced survival, but due to the nature of the study, the findings must be interpreted lightly [Beyer et al. 2005] . Currently, neither the AUA nor the EAU guidelines recommend the use of neoadjuvant HT with brachytherapy.
Hormone therapy following PSA recurrence Patients with PSAR continue to be the most common recipients of HT [Akaza et al. 2006 Immediate versus delayed therapy. For locallyadvanced and metastatic PCa, there is much debate about the best time to start therapy. Immediate or early therapy refers to the initiation of HT as soon as a patient's PSA begins to rise following surgery, whereas delayed therapy generally begins when clinical signs of metastatic disease are present. Only a few randomized trials for immediate versus delayed therapy exist today. The Medical Research Council, with a cohort of 983 men with locally-advanced or metastatic PCa, randomized men to immediate or delayed HT and found no survival difference between therapies. Patients receiving immediate therapy, however, did have significantly lower rates of pathological fractures, bone pain and ureteral obstruction [The Medical Research Council Prostate Cancer Working Party Investigators Group, 1997 ]. More recently, Moul and colleagues with the largest retrospective cohort to date with 1,352 patients, found that immediate therapy was associated with delayed clinical metastases in patients with a GS >7 or a PSA doubling time <12 months. No survival advantage was seen. A Cochrane review by Nair and colleagues concluded that immediate HT is associated with a small, but significant survival advantage at 10 years [Nair et al. 2002] . However, it also concluded that early therapy is associated with increased costs and more side-effects. Finally, a review by Messing and colleagues concluded that immediate HT may have a survival advantage for men with non-metastatic, lymph node positive disease [Messing et al. 2006 ]. Men with metastatic disease may not see a survival advantage, but will see improved QOL with HT.
Continuous versus intermittent therapy. As patients are undergoing HT for increasingly longer periods of time, providers are now faced with the challenge of how often to administer HT. Nearly all patients who undergo HT will eventually develop PCa that is resistant to therapy. This is termed castration-resistant PCa (CRPC) and currently there is little that physicians can do to treat the disease. A number of trials have been conducted comparing intermittent HT (IHT) with continuous HT (CHT). A number of trials in the past have concluded that IHT is no worse than CHT, but due to small sizes of the trials in question, limited recommendations have been made [Prapotnich et al. 2009; Peyromaure et al. 2005; De La Taille et al. 2003; Youssef et al. 2003] . A Cochrane review completed in 2007 found that there is not enough data to suggest that IHT is more effective than CHT for survival or disease progression and limited information suggests that IHT may have slightly reduced adverse events [Conti et al. 2007] . A recently completed randomized trial by Calais Da Silva that included 626 men with locally-advanced or metastatic disease found that men receiving IHT versus CHT were not significantly different with respect to survival. The IHT group had more cancer deaths, but less cardiovascular deaths. QOL was no different while undergoing treatment, though men on IHT had significantly better sexual activity and the overall cost was significantly reduced in the IHT group.
Currently the AUA does not have definitive recommendations regarding treatment initiation-time or treatment intervals for HT following PSAR. The EAU guidelines suggest that a period of watchful waiting may be appropriate with a possibility of HT at a later time. They also state that lymph node-positive disease may be an indication for immediate HT, but they do not go so far as to recommend it. For intermittent versus continuous therapy, the EAU guidelines state that IHT may be acceptable for some patients, but that randomized trials are needed.
Risks associated with hormone therapy HT continues to be a popular treatment option for men with recurrent or advanced PCa, however, the treatment is not without risks. Medical and surgical castration have been shown to be equally effective treatments for PCa [Vogelzang et al. 1995; Kaisary et al. 1991] , but today, for multiple reasons, medical options are more often utilized. However, regardless of therapy choice, both forms of treatment have significant side effects. LHRH agonists and surgical castration both effectively reduce testosterone levels and as a result have a similar side-effect profile, though there have been limited reports on orchiectomy alone. In addition there is limited data on antiandrogens, which makes valid comparisons between treatments difficult. Even with limited data on these specific therapies, a great amount of research has been conducted looking at LHRH agonists and anti-androgens.
Biochemical flare
A side effect specific to LHRH agonists is the flare phenomenon. Before the 'resetting' of the anterior hypothalamic-pituitary-gonadal axis, stimulation of the anterior pituitary with a LHRH agonist results in a surge of increased testosterone. The flare reaction is not seen in patients treated with other forms of castration. Thompson and associates demonstrated, in a review of 765 patients from 9 studies, that 10.9% of patients experienced a flare and 2% died [Thompson et al. 1990 ]. In patients with overt metastases who are at risk of developing symptoms associated with a surge in testosterone with initial LHRH agonist administration, anti-androgen therapy should precede or be co-administrated with the LHRH agonist and be continued in combination for at least 7 days [Schulze and Senge, 1990; Labrie et al. 1987 ]. An exception exists for patients at high risk of impending spinal cord compression, for whom surgical castration is recommended [Heidenreich et al. 2008] .
Sexual side effects
Sexual side effects are the most common among patients undergoing HT. However, recent research has demonstrated differences in sideeffect rates between HT with LHRH agonists and anti-androgens.
ADT. The side effects of LHRH agonists are comparable with those of castration, principally due to the reduction in testosterone levels to <50 ng/dl achieved by both therapies.
The list of side effects with HT is significant and patient considerations on QOL must be factored into any treatment decisions. Sexual side effects are reported at variables, but nonetheless there are high rates with castration. Decreased libido is reported in up to 90% of patients and erectile dysfunction levels vary among studies ranging between 1572% [Diblasio et al. 2008 Potosky et al. 2001] . In one study, Potosky and colleagues reported that sexual function among a cohort of 431 men was impaired similarly in patients undergoing either surgical or medical castration. In the study, 63.6 and 58.0% of patients (surgical and medical castration respectively) reported 'no interest' in sexual activity following HT, up from 27.6 and 31.7% before treatment [Potosky et al. 2001] . Diblasio, with a cohort of 359 patients, found an erectile-dysfunction rate of only 14% of patients following HT, but did admit that under-reporting likely played a role in the number [Diblasio et al. 2008 ]. Fowler and colleagues, with a cohort of over 1,300 men who underwent radical prostatectomy with or without HT, found that men receiving HT were significantly more likely to have decreased libido (69 versus 29% had 'no sex drive within the last 30 days') and were significantly more likely to have had no erections since surgery (72 versus 55%) [Fowler et al. 2002] .
Anti-androgens. Despite conflicting studies, the number of men receiving oral anti-androgen therapy alone has grown, in part due to the presumed decrease in sexual side effects associated with therapy. One study by Iversen and colleagues showed men receiving anti-androgens were much more likely to maintain sexual interest (64%) versus men receiving ADT (30%) ]. See and Tyrrell found that patients given bicalutamide at a dose of 150 mg/ day before radiotherapy had rates of impotence (12.7%) and decreased libido (4%) that were not statistically different from men receiving placebo. These results are much lower than reported rates for men undergoing more traditional ADT [See and Tyrrell, 2006 ].
Osteoporosis and fractures
As patients continue to receive HT for longer periods of time, osteoporosis has emerged as a significant risk of treatment.
ADT. ADT has been shown to increase the risk of osteoporosis and pathological fractures in multiple studies [Malcolm et al. 2007; Smith et al. 2006a; Shahinian et al. 2005; Preston et al. 2002] . Longer-term treatment with ADT, increased age (>70) at treatment initiation and CHT have all been shown to increase rates of osteoporosis and fractures [Malcolm et al. 2007] . Reported rates of osteoporosis vary widely within the literature, with a range of 723% [Malcolm et al. 2007; Shahinian et al. 2005 ]. Rates of fractures in patients on ADT also vary widely between studies, with a range of approximately 520% with fracture rates for control patients generally in the range of 0.712% [Malcolm et al. 2007; Smith et al. 2006a; Lopez et al. 2005; Shahinian et al. 2005; Oefelein et al. 2001; Hatano et al. 2000; Townsend et al. 1997 ]. Lopez and colleagues found a four-fold increase in fracture risk in patients on CAB [Lopez et al. 2005 ]. Shahinian and associates looking at a cohort of more than 50,000 men, found ADT was associated with a significant increase in osteoporosis (0.596.92% versus 0.463.59% for non-ADT patients) and fractures (3.4119.37% versus 2.812.63%) [Shahinian et al. 2005] .
A number of trials have shown that the administration of bisphosphonates during ADT can increase bone-mineral density (BMD). Yuen and colleagues in a review of 1,955 patients found bisphosphonate administration led to significant decreases in pain and skeletal events (fractures, spinal cord compression and bone surgery) [Yuen et al. 2006 ]. Others have demonstrated that taking pamidronate during HT reduces bone loss in the hip and lumbar spine [Diamond et al. 2001; Smith et al. 2001] . Perhaps the most important agent for overall skeletal health for men with PCa, with metastases or undergoing HT, is zoledronic acid. It has been shown to prevent bone loss in patients with locally-advanced PCa receiving HT [Polascik and Mouraviev, 2008; Ryan et al. 2006 ]. In addition, zoledronic acid has been shown to reduce the number of skeletal-related events (SRE) in men with CRPC [Polascik et al. 2005; Saad et al. 2004; 2002] .
Anti-androgens. Anti-androgen therapy, unlike ADT, has not been shown to increase the risk of osteoporosis. A number of smaller trials have demonstrated reduced rates of osteoporosis with anti-androgen use versus ADT [Sieber et al. 2004; Smith et al. 2004; Tyrrell et al. 2003 ]. Wadhwa and colleagues in a prospective trial of 618 men randomized to LHRH agonist or anti-androgen, showed that men on anti-androgen, therapy maintained BMD whereas those taking a LHRH agonist had a significant loss. The exact mechanism through which anti-androgens may decrease the risk of osteoporosis in unknown, however, it is known that the drugs effectively block the effects of testosterone while allowing serum testosterone levels to remain normal or elevated. It has been suggested that the increased testosterone levels, through peripheral aromatization, may lead to higher levels of estrogen which in turn may slow the rate of bone loss [Verhelst et al. 1994 ]. Randomized trials are needed to confirm the effects of anti-androgens on osteoporosis, however preliminary findings are encouraging.
Metabolic issues
ADT is associated with significant body composition/metabolic changes including increased rates of metabolic syndrome, diabetes, hypercholesterolemia, hypertriglyceridemia, and coronary artery disease (CAD) [Kintzel et al. 2008; Braga-Basaria et al. 2006a ]. Increased body fat and reduced lean-muscle mass are well-known effects of ADT [Van Londen et al. 2008; Smith, 2004; Berruti et al. 2002; Chen et al. 2002] with fat content increasing up to 20% in one study and lean body mass decreasing by 3.8%. Often these changes are evident in the first 36 months of ADT [Smith et al. 2006b; Berruti et al. 2002 ]. Keating and colleagues showed that ADT was associated with increased levels of diabetes (Hazard ratio (HR) ¼ 1.44 for LHRH agonist and 1.34 for orchiectomy), but interestingly found that only treatment with a LHRH agonist, and not orchiectomy, was associated with increased risk for CAD, MI and sudden cardiac death [Keating et al. 2006 ]. Saigal and colleagues found that men receiving ADT for at least 1 year were at a 20% higher risk of serious cardiovascular morbidity than men not receiving ADT. They also found that risk began within 12 months of treatment initiation. Anti-androgen therapy has not been associated with significant metabolic side effects [Saigal et al. 2007 ].
Cognitive issues
As HT duration has increased, cognitive decline has become a more discussed potential side effect. Within the last decade a large number of studies have demonstrated the relationship between HT and subtle, but significant cognitive changes. A review performed by Nelson and associates showed the three cognitive areas that were affected most often by ADT were visuospatial abilities, working memory and executive functioning . To our knowledge, no large studies have examined antiandrogen therapy and cognitive decline.
Additional side effects
Gynecomastia and breast tenderness are the most commonly reported side effects of oral antiandrogen therapy alone with rates as high as 67.1 and 75.1%, respectively. ADT is generally associated with significantly lower rates with reports of gynecomastia and breast tenderness as low as 3.8 and 1.9% respectively ]. Potosky and colleagues reported gynecomastia rates of 24.9 and 9.7% for patients on LHRH agonists and receiving orchiectomy respectively [Potosky et al. 2001] .
Hot flashes are another unpleasant, but common side effect of ADT with incidence rates ranging from 50-80% [Sharifi et al. 2005; Holzbeierlein et al. 2004; Higano, 2003; Chen et al. 2002; Potosky et al. 2001] . Up to 30% of men on ADT report hot flashes as the most debilitating side effect of therapy [Sharifi et al. 2005; Holzbeierlein et al. 2004; Chen et al. 2002] .
Rates of hot flashes for medical and surgical castration patients are similar with some reports suggesting a slightly, but not statistically significant, reduced incidence in men receiving orchiectomy [Higano, 2003; Potosky et al. 2001; Sarosdy et al. 1999; Parmar et al. 1987] . Hot flashes are reported at much lower rates (1015%) with anti-androgen therapy [See et al. 2006; Iversen et al. 1998 ].
Risk Stratification for hormone therapy For many years, patients with PSAR have effectively fallen into their own category making further treatment stratification difficult. This is in large part due to a lack of randomized trials and the resultant dearth of prognostic data for patients who have initiated HT. As a result, knowing the optimal balance of risks and rewards is complicated. Some trials however have reported prognostic factors for men undergoing HT and though the trials are designed to look at different aspects of HT, themes have started to emerge.
Stratification factors for HT
Trials looking at the effects of HT are increasing in popularity as the treatment modality is becoming more utilized. To date, there have been no trials examining the effects of HT on subgroups of patients based on clinical or pathological characteristics (such as GS, PSA level, etc). However, as research efforts have increased, trends have started to emerge. These results and future trials may help physicians determine who will gain the most benefit from HT. Below is a summary of some of the factors found to be predictive of HT outcomes. A complete list of findings from trials is seen in Table 1. PSA-related factors. While PSA levels have been shown to predict PSAR and prostate cancer specific mortality (PCSM), few studies have specifically examined the predictive power of PSA as it relates to HT. A number of studies have found that PSA-related factors including pretreatment PSA, PSA nadir level and PSA doubling time (PSADT) may identify patients at higher risk of HT failure or PCSM. In a large study that looked at 1,076 patients with metastatic PCa, Glass and colleagues found that a PSA < 65 ng/ml significantly predicted 5-year survival in patients receiving HT [Glass et al. 2003 ]. A number of smaller studies have demonstrated that factors such as a higher PSA nadir after initiation of HT and PSADT < 12 months predict worse outcomes for men on HT [Choueiri et al. 2009; Chung et al. 2008; Studer et al. 2008; Scholz et al. 2007; Tenenholz et al. 2007 ].
Finally, Hussain, with a cohort of 1,345 men with metastatic disease undergoing intermittent or continuous ADT, found that a PSA nadir between 0.24 ng/ml and PSA nadir <0.2 ng/ml were significant predictors of survival (HR ¼ 0.30 and HR ¼ 0.17 respectively) [Hussain et al. 2006 ].
Though no specific levels have been determined, data show that a higher PSA level at treatment time, a higher PSA nadir following treatment and a faster PSADT (both before definitive treatment and HT) are all correlated with worse outcomes.
Gleason score. GS is another factor that is consistently found to predict negative outcomes both before definitive treatment and HT. A GS > 7 is generally regarded as aggressive disease. Prapotnich and colleagues in a nonrandomized trial including 566 men on ADT, found that a GS > 7 was predictive of increased mortality [Prapotnich et al. 2009 ]. Additionally, Ross   Table 1 . Summary of risk stratification results from previous hormone therapy (HT) trials.
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HT therapy Findings
HT after curative therapy Glass [Glass et al. 2003 ] Orchiectomy +/À flutamide GS < 8 and PSA < 65 ng/ml significantly predicted 5 year survival Thompson [Thompson et al. 2001] Orchiectomy +/À flutamide African American race, GS > 8 and bone pain significantly predicted lower 5 year survival Chung [Chung et al. 2008] Orchiectomy, LHRH agonists, anti-androgens or CAB High PSA at HT initiation, GS > 7, PSA nadir >0.9 ng/ml significantly predicted PCSM Rodrigues [Rodrigues et al. 2006 ] ADT -No further definition given PSA nadir >0.2 ng/ml and GS > 7 significantly predicted PCSM Choueiri [Choueiri et al. 2009] Orchiectomy, LHRH agonists and CAB PSA time to nadir <6 months, GS > 7, PSA nadir >0.2 ng/ml predicted shorter overall survival Ross [Ross et al. 2008] Orchiectomy, LHRH agonist and CAB With metastates GS > 7 predicted shorter time to progression. Without metastases PSA predicted shorter time to progression. Previous ADT predicted shorter time to progression for both. Porter [Porter et al. 2007] Orchiectomy or LHRH agonist Pathologic stage >T3 predicted PCa specific mortality Scholz [Scholz et al. 2007] LHRH agonist +/À anti-androgen PSA nadir >0.05 ng/ml and PSADT < 12 months were predictive of PCSM Banez [Banez et al. 2009] Flutamide with or without finasteride PSA > 4 ng/ml before HT initiation was predictive of disease progression Hussain [Hussain et al. 2006] CAB PSA nadir >4 ng/ml after 7 months of ADT, GS > 7 and bony pain was significantly predictive of decreased survival. HT as primary treatment Janoff [Janoff et al. 2005] Orchiectomy or LHRH agonists Age < 70 and GS > ¼ 6 were found to be at higher risk for treatment failure Graff [Graff et al. 2007] Orchiectomy, LHRH agonists and CAB GS > ¼ 7, PSA > ¼ 20 ng/ml and a low number of co-morbidities significantly predicting PCSM Intermittent versus continuous HT Prapotnich [Prapotnich et al. 2009] CAB after primary failure Age < 60, PSA >100 and GS > 7 were predictive of mortality in patients undergoing intermittent CAB Irani [Irani et al. 2008] CAB Disease progression was associated with PSA and GS. GS was predictive of PCSM Immediate versus delayed HT Studer [Studer et al. 2008] Orchiectomy or LHRH agonist PSADT ¼ <12 months and PSA > 50 ng/ml at treatment initiation were predictive of increase mortality for patients who underwent delayed ADT Tenenholz [Tenenholz et al. 2007] Orchiectomy, LHRH agonist, anti-androgen, or DES PSA > 15 ng/ml, PSADT 7 months, log of PSADT and log PSA were predictive of overall survival. Log of PSADT was significantly predictive of disease specific survival. Moul [Moul et al. 2004] LHRH agonist, orchiectomy or CAD HT delayed clinical metastases in patients with GS > 7 and PSADT ¼<12 months ADT, androgen deprivation therapy; CAB, complete androgen blockade; DES, diethylstilbestrol; GS, Gleason score; LHRH, luteinizing hormonereleasing hormone; PCSM, prostate cancer-specific mortality; PSA, prostate specific antigen; PSADT, PSA doubling time.
found that a GS > 7 was correlated with shorter time to progression in patients undergoing ADT with metastatic disease, but not in those without metastases [Ross et al. 2008] . Finally, in a large trial, Glass and colleagues found that a GS > 7 was a significant predictor of decreased survival in patients undergoing HT [Glass et al. 2003 ].
As with previously described factors, there is no GS that has been definitively shown to predict worse outcomes. However, increasing GS, especially above 7, has consistently been associated with decreased survival and treatment failure.
Race. Being of African American (AA) race is a known predictor of PSAR, but limited studies have examined race as it pertains to HT outcomes. In a large trial of 1,263 men with metastatic PCa who received orchiectomy with or without flutamide, Thompson and colleagues found that AA race was a significant predictor of decreased overall survival [Thompson et al. 2001] . More studies are needed to determine why this relationship exists.
Summary of risk factors
Based on a limited number of trials reporting factors predictive of success or failure with HT as well as a shortage of randomized trials, it is difficult to make definitive recommendations as to which patients are best suited for HT. Nevertheless, emerging trends from available trials suggest that distinct clinico-pathological characteristics, including elevated PSA, rapid PSADT, high PSA nadir following therapy and GS > 7, may give prognostic information as to which patients are likely to gain the most benefit from HT. This information and future findings are likely to lead to risk stratification guidelines for men undergoing HT for PCa.
Conclusion
HT continues to be a common treatment option for recurrent PCa and locally advanced PCa. Both long-and short-term treatment courses are associated with many undesirable side effects which can lead to decreased QOL. There are only a few circumstances in which HT is clearly indicated:
(1) For patients with high risk disease that are undergoing radiation therapy; (2) To shrink the prostate before brachytherapy (though there has been no survival advantage demonstrated); and
(3) To palliate symptoms in patients with metastatic PCa [Heidenreich et al. 2008; Thompson et al. 2007 ].
Treatment with anti-androgens has been shown to be inferior to ADT for patients with metastatic disease ]. For patients with recurrent disease after definitive treatment, there is little data suggesting a survival advantage from the use of HT, however much data exists to support the palliate ability of the treatment.
Both LHRH agonists and anti-androgens are associated with significant side effects. Treatments with anti-androgens have much lower rates of sexual side effects, hot flashes and osteoporosis. Anti-androgens are also not known to cause biochemical flare. Treatment with ADT results in lower rates of gynecomastia and breast tenderness.
Emerging research has shown that HT may be associated with increased rates of metabolic and cardiac complications as well as cognitive declines. CAB has been shown to produce a small, but significant increase in overall survival, but cost considerations and side effects should be taken into consideration. Treatment with LHRH antagonists and TAB are not well studied.
Questions remain as to the best time to initiate treatment, the optimal duration, the best treatment schedule and most importantly, which patients are the most likely to benefit from HT. Patient stratification based on clinical and pathological factors remains ambiguous and though results from trials are limited, some trends have started to materialize. Patients undergoing HT and with characteristics including a PSADT 12 months, GS > 7, PSA nadir >0.2 ng/ml and elevated PSA at time of HT may be at increased risk of disease progression and ultimately PCSM, though additional studies are needed to confirm these initial findings.
In the end, communication is paramount in determining optimal therapy for individual patients. Before initiation of HT, clinicians should carefully consider the factors that have been shown to correlate with poor HT outcomes, and patients should be made aware of the potential adverse effects and risks associated with different HT treatment options. This combination of efforts gives patients and providers the best chance at achieving the optimal balance of risk and benefit. Galalae, R.M., Martinez, A., Mate, T., Mitchell, C., Edmundson, G., Nuernberg, N. et al. (2004) Longterm outcome by risk factors using conformal highdoserate brachytherapy (HdrBt) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58: 10481055.
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